Keytruda (Pembrolizumab) Patent Expiration, LOE Window & CMS Spending
Keytruda (Pembrolizumab) by Merck & Co.: Biologic BLA (Purple Book Regime), 0 AB generics, $969.5M 2024 CMS Part D & Medicaid spend, and $24,063 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | B125514 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $969.5M |
| 2024 Medicare Part D Spend | $140.1M |
| 2024 Medicaid Spend | $829.4M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($24,063 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.